Replies to post #3983 on InMed Pharmaceuticals Inc (INM)

[Flair09]

I bet they license out Their biosynthesis and Bioinformatics within the next 12 months. They're going to make Billions from that before any of their pipelines finish CT's. Shoot a partnership could be announced tomorrow. Lesgetrich already told you how the pps works. Hate to tell you, I'll listen and take his advice before yours. That man knows his sh**! Even if they don't start generating revenue like you say for a while, the potential and the future of this company will drive the price up. It's all good make your money on the dump days! I don't blame you. The lows will keep getting higher and the highs will keep getting higher until that one day that huge PR comes out and we all make a killing.

[greenwillow]

Markets are forward looking, my friend.

Great example, GW Pharmaceutical

New support in low 70's with IMLFF, get on board or get left behind.

It looking great this morning.

GLTA
GW

[spriots]

The “classic” pump and dump... would that involve insiders “dumping” their shares as the price goes up? What insiders have sold?

[IAmTopG]

I know this is an extreme example. AMZN did not make money for years. People invested in that sh$#% See where they are now.

[gone3uo6]

There is definitely some pump/dump, but that isn't the only thing going on. The provisional applications for patents is in place to allow the company time to prepare for the non-provisional applications coming soon (provisional applications are good for 1 year IIRC). On the company's website they have their pipeline schedule posted with trials set to begin in 2018 and beyond.

Inmed is the only company out there with a provisional application in place (that I know of) for biosynthesis of cannabinoids. I believe other companies like Isodiol are doing herbal extraction or chemical synthesis, which are costly compared to biosynthesis. This, coupled with the recreational legalization in Canada looming, is most likely driving Inmed's current gains--despite recreational cannabis use having nothing to do with what Inmed is doing.